1887
Volume 2023, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Background: Managing a high-risk pulmonary embolism (PE) in a critically ill patient with severe thrombocytopenia can present a challenging dilemma. There is a high risk of fatal bleeding due to anticoagulation in high-risk PE with thrombocytopenia; therefore, risks and benefits are balanced while dealing with such a critical scenario.

Case Report: We present a case of a female patient with thrombocytopenia who was admitted for management of lymphoma. Her hospital course was complicated by high-risk PE, leading to acute respiratory failure and hypotension, necessitating urgent transfer to the medical intensive care unit. She was intubated and placed on mechanical ventilation. Multiple cardiac arrests occurred due to compromised cardiac output from a severely dilated right ventricle on bedside transthoracic echocardiography. As a last resort to save her life in this critical state and severe thrombocytopenia, she was given a half bolus dose of the recommended drug, i.e., 50mg IV of Alteplase. Subsequently, she stabilized and was extubated without any further complications.

Discussion: High-risk PE needs prompt management with anticoagulation to avoid fatal outcomes. However, on the other hand, anticoagulation carries a high risk of bleeding, especially in patients with thrombocytopenia. These challenges prompt a modern perspective in situations where clear guidelines are absent.

Conclusion: We aim to discuss our contemporary clinical practice in managing such a complex case and highlight the need for further studies.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2023.39
2024-01-06
2024-07-24
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2023/4/qmj.2023.39.html?itemId=/content/journals/10.5339/qmj.2023.39&mimeType=html&fmt=ahah

References

  1. Sadeghi A, Brevetti GR, Kim S, Burack JH, Genovese MH, Distant DA, et al.. Acute massive pulmonary embolism: role of the cardiac surgeon. Tex Heart Inst J. 2005; 32:(3):430-3.
    [Google Scholar]
  2. Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013; 18:(2):129-38.
    [Google Scholar]
  3. QiMin W, LiangWan C, DaoZhong C, HanFan Q, ZhongYao H, XiaoFu D, et al.. Clinical outcomes of acute pulmonary embolectomy as the first-line treatment for massive and submassive pulmonary embolism: a single-centre study in China. J Cardiothorac Surg. 2020 Oct 21; 15:(1):321. doi: 10.1186/s13019-020-01364-z.
    [Google Scholar]
  4. Iaccarino A, Frati G, Schirone L, Saade W, Iovine E, D’Abramo M, et al.. Surgical embolectomy for acute massive pulmonary embolism: state of the art. J Thorac Dis. 2018; 10:(8):5154-61. doi: 10.21037/jtd.2018.07.87.
    [Google Scholar]
  5. Sekhri V, Mehta N, Rawat N, Lehrman SG, Aronow WS. Management of massive and nonmassive pulmonary embolism. Arch Med Sci. 2012 Dec 20; 8:(6):957-69. doi: 10.5114/aoms.2012.32402.
    [Google Scholar]
  6. Keeling WB, Sundt T, Leacche M, Okita Y, Binongo J, Lasajanak Y, et al.. Outcomes After Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus: A Multi-Institutional Study. Ann Thorac Surg. 2016 Nov; 102:(5):1498-1502. doi: 10.1016/j.athoracsur.2016.05.004.
    [Google Scholar]
  7. Leacche M, Unic D, Goldhaber SZ, Rawn JD, Aranki SF, Couper GS, et al.. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005 May; 129:(5):1018-23. doi: 10.1016/j.jtcvs.2004.10.023.
    [Google Scholar]
  8. Kucher N, Goldhaber SZ. Management of Massive Pulmonary Embolism. Circulation. 2005; 112:(2):e28-e32. doi: 10.1161/CIRCULATIONAHA.105.551374.
    [Google Scholar]
  9. Tanous O, Dujovny T, Hertzel G, Koren A, Levin C. Immune Thrombocytopenia Secondary to Hodgkin’s Lymphoma in Children. Isr Med Assoc J. 2020; 22:(4):224-6.
    [Google Scholar]
  10. Hauswirth AW, Skrabs C, Schützinger C, Raderer M, Chott A, Valent P, et al.. Autoimmune thrombocytopenia in non-Hodgkin’s lymphomas. Haematologica. 2008 Mar; 93:(3):447-50. doi: 10.3324/haematol.11934.
    [Google Scholar]
  11. Fugate JE, Rabinstein AA. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke. Neurohospitalist. 2015; 5:(3):110-21. doi: 10.1177/1941874415578532.
    [Google Scholar]
  12. Muñoz Tovar RA, Alvarez Perdomo LC, Rojas Molina SM, Salazar SJ. Submassive Pulmonary Thromboembolism in a Patient with Thrombocytopenia: Therapeutic Challenge. Case Rep Crit Care. 2019 Jan 22; 2019::1919401. doi: 10.1155/2019/1919401.
    [Google Scholar]
  13. Kiser TH, Burnham EL, Clark B, Ho PM, Allen RR, Moss M, et al.. Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism. Crit Care Med. 2018; 46:(10):1617-25. doi: 10.1097/CCM.0000000000003288.
    [Google Scholar]
  14. Yilmaz ES, Uzun O. Low-dose thrombolysis for submassive pulmonary embolism. J Investig Med. 2021 Dec; 69:(8):1439-1446. doi: 10.1136/jim-2021-001816.
    [Google Scholar]
/content/journals/10.5339/qmj.2023.39
Loading
/content/journals/10.5339/qmj.2023.39
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): high-risk PElymphomasevere thrombocytopenia and thrombolysis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error